Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

3.6K
Commitment is the  process whereby stem cells:
3.6K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.7K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.7K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.2K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDB1-dependent enhancer connectivity defines T-cell leukemia identities and masks metabolic vulnerabilities.

bioRxiv : the preprint server for biology·2026
Same author

The H3K4 methyltransferase KMT2D is an essential cofactor for GATA1 at erythroid gene enhancers.

Nature communications·2026
Same author

A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.

Nature reviews. Cancer·2026
Same author

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

Leukemia·2026
Same author

Adult <i>TWIST2</i>-high B-ALL confirms metabolic association but reveals molecular heterogeneity.

HemaSphere·2026
Same author

Control of naive T cell reactivity and peripheral tolerance by ascorbate and TET activity.

Science advances·2026

Related Experiment Video

Updated: Nov 2, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K

Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia.

Lindsey E Montefiori1, Sonja Bendig2, Zhaohui Gu3,4

  • 1Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Cancer Discovery
|June 9, 2021
PubMed
Summary
This summary is machine-generated.

We discovered a new type of acute leukemia driven by abnormal BCL11B gene activity. This deregulation, caused by genetic rearrangements, leads to mixed myeloid and T-cell leukemia by keeping cells in a primitive state.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Experiment Videos

Last Updated: Nov 2, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Lineage-ambiguous leukemias are aggressive cancers with unknown genetic causes.
  • Understanding the molecular drivers is crucial for diagnosis and treatment.

Purpose of the Study:

  • To identify the genetic basis of a specific subgroup of lineage-ambiguous acute leukemia.
  • To elucidate the mechanism of BCL11B deregulation in these cancers.

Main Methods:

  • Analysis of chromosomal rearrangements and focal amplifications.
  • Chromatin conformation capture techniques.
  • Gene expression profiling of myeloid, T lymphoid, and stem cell markers.

Main Results:

  • Identified a distinct leukemia subgroup with aberrant allele-specific BCL11B deregulation.
  • Found that chromosomal rearrangements juxtapose BCL11B to superenhancers or create new ones.
  • Demonstrated aberrant BCL11B co-option into progenitor cell regulatory networks.

Conclusions:

  • Ectopic BCL11B expression in primitive hematopoietic cells, driven by enhancer hijacking, is an oncogenic driver in lineage-ambiguous leukemia.
  • This finding provides a molecular basis for a subset of leukemias that defy current classification.
  • Highlights BCL11B deregulation as a key feature transcending diagnostic boundaries.